The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info‚ÄĒit‚Äôs all here.

Press Release

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Calidi Biotherapeutics announced a new patent for its SuperNova technology, advancing its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccine. This strengthens Calidi’s position in developing innovative therapies for advanced solid tumors.

A close up of a cell in the air.
Press Release
event
SuperNova (SNV)
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Calidi Biotherapeutics announced a new patent for its SuperNova technology, advancing its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccine. This strengthens Calidi’s position in developing innovative therapies for advanced solid tumors.

July 18, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi

July 16, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova

Calidi to Effect Reverse Stock Split

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (‚ÄúCalidi‚ÄĚ or ‚ÄúCompany‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today announced that its Board of Directors has approved the reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 (the ‚ÄúReverse Stock Split‚ÄĚ).

July 5, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or "Calidi") has appointed Dr. George E. Peoples, MD, FACS, to the company's Board of Directors, effective July 1, 2024. Calidi is a clinical-stage biotechnology company that is developing a new generation of targeted antitumor virotherapies.

June 27, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

The exclusive event, hosted by RedChip Companies, will feature Calidi Biotherapeutics Chief Business Officer Stephen Thesing and Chief Financial Officer Andrew Jackson, who will share insight into the Company’s proprietary technology platforms and current development pipeline.

June 11, 2024
Discover More
Discover More
Discover More
Press Release
event
RTNova
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that it entered into a collaboration agreement with SIGA Technologies (Nasdaq: SIGA) in the first quarter of 2024, to support the development of Calidi‚Äôs systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.

June 10, 2024
Discover More
Discover More
Discover More
Press Release

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of three abstracts in a poster session during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2024
Discover More
Press Release

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has entered a definitive agreement for the immediate exercise of Series B and C warrants, expected to generate approximately $2.1 million. The new unregistered warrants issued will have a five-and-a-half-year term and an exercise price of $0.30 per share, pending shareholder approval. The proceeds will support Calidi's clinical and pre-clinical programs, operational expenses, and working capital.

May 31, 2024
Discover More
Press Release

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

May 14, 2024
Discover More
Press Release

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois.

May 1, 2024
Discover More
Press Release

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants, Series B Unit Warrants, with each unit consisting of one share of common stock and a Series B-1 Common Warrant and Series C Unit Warrants, with each unit consisting of one share of common stock and a Series C-1 Common Warrant at an effective combined price of $0.40 per share and common warrants for aggregate gross proceeds of approximately $6.1 million, before deducting placement agent fees and other offering expenses. The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately. The common warrants will expire in five years (with respect to the Series A Common Warrant, the Series B-1, Warrant and the Series C-1 Common Warrant), twelve months (with respect to the Series B common warrants) and four months (with respect to the Series C common warrants) from the issuance date.

April 19, 2024
Discover More
Press Release

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Calidi Biotherapeutics announces a public offering to raise $6.1 million closing by April 18, 2024.

April 16, 2024
Discover More
Publication
event
RTNova
RTNova
NeuroNova
Supernova

Transforming Tumor Immune Microenvironments with a Novel Systemic Enveloped Oncolytic Virotherapy Targeting All Tumor Sites

ASCO Annual Meeting 2024

June 1, 2024
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova

Non-Clinical Evidence Supporting the Upcoming CLD-201 Clinical Trial: Cell-Based Oncolytic Virotherapy for Multiple Solid Tumors

ASCO Annual Meeting 2024

June 1, 2024
Discover More
Discover More
Publication
event
NeuroNova (NNV)
NeuroNova (NNV)
NeuroNova
Supernova

Phase 1 Study of Multiple Intracerebral Doses of a Neural Stem Cell-based Oncolytic Virotherapy for Treatment of Recurrent High-grade Gliomas

ASCO Annual Meeting 2024

June 1, 2024
Discover More
Discover More
Publication
event
NeuroNova & SuperNova
NeuroNova & SuperNova
NeuroNova
Supernova

Stem Cell Platforms for Enhanced Oncolytic Virotherapy

Festival of Biologics

April 16, 2024
Discover More
Discover More
Publication
event
NeuroNova & SuperNova
NeuroNova & SuperNova
NeuroNova
Supernova

Deciphering Anticancer Mechanisms of Oncolytic Virus-loaded Stem Cells

American Association for Cancer Research

April 9, 2024
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova

Annual Meeting ‚Äď SITC 2023 ‚Äď Nov 1st to 5th 2023 in San Diego, CA, USA.

SUPERNOVA1 (SNV1), A NOVEL ONCOLYTIC-CELL BASED PLATFORM FOR CANCER THERAPY

November 3, 2023
Discover More
Discover More
Media

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

February 3, 2024
Media

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

February 3, 2024
Media

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

February 3, 2024
Media

Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.

February 3, 2024
Media

Big Biz TV - Allan Camaisa

Pioneering Progress: Calidi Biotherapeutics CEO Allan Camaisa Unveils Latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023
Media

Big Biz TV - Stephen Thesing

Pioneering Progress: Calidi Biotherapeutics CBO Stephen Thesing discusses the latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023
In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023
Discover More
Discover More
In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023
Discover More
Discover More

All Courses

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more